GlaxoSmithKline PLC (NYSE:GSK)

41.91
Delayed Data
As of May 29
 +0.37 / +0.89%
Today’s Change
31.43
Today|||52-Week Range
48.25
-10.81%
Year-to-Date
Is Pfizer a Great Dividend Stock?
May 30 / MotleyFool.com - Paid Partner Content
GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada
May 19 / MotleyFool.com - Paid Partner Content
GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021
May 28 / MotleyFool.com - Paid Partner Content
23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus
May 19 / MotleyFool.com - Paid Partner Content
At Last, Merck Is Diving Into Coronavirus Vaccine and Antiviral Development
May 26 / MotleyFool.com - Paid Partner Content
Where Will Adaptimmune Be in 5 Years?
May 19 / MotleyFool.com - Paid Partner Content
Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?
May 23 / MotleyFool.com - Paid Partner Content
Why Vir Biotechnology Rocketed Higher Today
May 18 / MotleyFool.com - Paid Partner Content
GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test
May 21 / MotleyFool.com - Paid Partner Content
France piles pressure on Sanofi over coronavirus vaccine plans
May 15 / CNN.com - Paid Partner Content
Better Buy: GlaxoSmithKline vs. Pfizer
May 20 / MotleyFool.com - Paid Partner Content